Johnson & Johnson (NYSE:JNJ) Shares Sold by Kellett Wealth Advisors LLC

Kellett Wealth Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 16.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,649 shares of the company’s stock after selling 320 shares during the quarter. Kellett Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $238,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in JNJ. IFS Advisors LLC boosted its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $31,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $35,000. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ? increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Barclays increased their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Raymond James cut their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Stifel Nicolaus cut their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Up 0.9 %

Shares of JNJ opened at $165.23 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a 50 day simple moving average of $150.90 and a 200-day simple moving average of $156.06. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market cap of $397.81 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the company posted $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.